About AREVA Med
AREVA Med is an AREVA subsidiary created in 2009 to develop innovative therapies to fight cancer.
Learn more about nuclear medicine and targeted alpha therapy (TAT) with lead-212, and about our ongoing research.
AREVA Med launched the first Phase 1 clinical trial of lead-212 (patient enrollment completed in 2014).
News & Materials
Read about the latest news and events, watch a video, or download our brochure.
Macrocyclics, an AREVA Med company, is the global leader in chelating agent technologies for medicine.
AREVA Med’s Second Production Facility on Schedule to Open in 2nd Quarter of 2016Read more
AREVA Med Launches Construction in the U.S. of Second Facility to Produce Lead-212 Used for Developing Cancer TreatmentsRead more